Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Filing 1026

MOTION in Limine to Preclude Amgen from Using Alleged Claim Features to Distinguish Prior Art when those Claim Features were Not Proven to Establish Infringement by F. Hoffmann-LaRoche LTD, Roche Diagnostics GmbH, Hoffmann LaRoche Inc..(Toms, Keith)

Download PDF
Amgen Inc. v. F. Hoffmann-LaRoche LTD et al Doc. 1026 Case 1:05-cv-12237-WGY Document 1026 Filed 09/10/2007 Page 1 of 3 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS AMGEN INC., Plaintiff, v. F. HOFFMANN-LA ROCHE LTD, ROCHE DIAGNOSTICS GmbH, and HOFFMANNLA ROCHE INC., Defendants. ) ) ) ) Civil Action No.: 05 Civ. 12237 WGY ) ) ) ) ) ) ) DEFENDANTS' MOTION IN LIMINE TO PRECLUDE AMGEN FROM USING ALLEGED CLAIM FEATURES TO DISTINGUISH PRIOR ART WHEN THOSE CLAIM FEATURES WERE NOT PROVEN TO ESTABLISH INFRINGEMENT Defendants F. Hoffmann-La Roche Ltd, Roche Diagnostics GmbH, and Hoffmann-La Roche Inc. (collectively "Roche") respectfully request that Amgen Inc. ("Amgen") be precluded from submitting evidence of--or arguments based on--structural and functional characteristics that allegedly distinguish the pharmaceutical composition of `422 claim 1 from the prior art, if, in moving summary judgment of infringement, Amgen did not show that CERA (the active ingredient in Roche's product, MIRCERAŽ) has those characteristics. In support of its motion for summary judgment of infringement of `422 claim 1 (D.N. 509), Amgen relied on a perfunctory analysis of whether CERA satisfied the requirements of `422 claim 1. However, for its attempt to distinguish the claimed subject matter over the prior art of naturally occurring EPO, Amgen apparently intends to read many more requirements into the claim. Simply put, having obtained summary judgment that Roche infringes `422 claim 1 based on a broad interpretation of the claim, Amgen should not be allowed to change the scope of the claim for purposes of the Court's validity analysis. 736822_1 Case 1:05-cv-12237-WGY Document 1026 Filed 09/10/2007 Page 2 of 3 In support of its motion, Roche offers the accompanying memorandum of law. CERTIFICATE PURSUANT TO LOCAL RULE 7.1 I certify that counsel for the parties have conferred in an attempt to resolve or narrow the issues presented by this motion and that no agreement could be reached. Dated: September 10, 2007 Boston, Massachusetts Respectfully submitted, F. HOFFMANN-LA ROCHE LTD, ROCHE DIAGNOSTICS GMBH, AND HOFFMANN-LA ROCHE INC. By their Attorneys, /s/ Keith E. Toms Lee Carl Bromberg (BBO# 058480) Timothy M. Murphy (BBO# 551926) Julia Huston (BBO# 562160) Keith E. Toms (BBO# 663369) Nicole A. Rizzo (BBO# 663853) Bromberg & Sunstein LLP 125 Summer Street Boston, MA 02110 Tel. (617) 443-9292 Leora Ben-Ami (pro hac vice) Mark S. Popofsky (pro hac vice) Patricia A. Carson (pro hac vice) Thomas F. Fleming (pro hac vice) Howard S. Suh (pro hac vice) Christopher T. Jagoe (pro hac vice) Kaye Scholer LLP 425 Park Avenue New York, New York 10022 Tel. (212) 836-8000 736822_1 2 Case 1:05-cv-12237-WGY Document 1026 Filed 09/10/2007 Page 3 of 3 CERTIFICATE OF SERVICE I hereby certify that this document filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF) and paper copies will be sent to those indicated as non registered participants on the above date. /s/ Keith E. Toms Keith E. Toms 3099/501 736822 736822_1 3

Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.

Why Is My Information Online?